Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2024 | $4.00 | Buy | Craig Hallum |
| 11/2/2022 | $5.00 | Outperform | Robert W. Baird |
| 6/14/2022 | $4.00 | Buy | B. Riley Securities |
| 8/19/2021 | $8.00 | Outperform | Noble Capital Markets |
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The 3rd Annual H.C. Wainwright BioConnect Investor Conference takes place on Tuesday, May 20, 2025, at the Nasdaq stock exchange headquarters in New York, NY. Investors interested in scheduling an in-person meeting with the Lineage management te
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at Clinical Trials at the Summit (CTS) 2025. CTS will be held June 20 - 21, 2025, and brings together a diverse group of experts from around the world to discuss ongoing clinical trials and the latest data, all with the goal of achieving advances in vit
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7
10-Q - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on Monday, March 10, 2025, by di
OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000® Index Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. "We were delighted to see our partners' continued commitment to the OpRegen program, in this instance by seeking
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived exp
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samuel III as Lineage's General Counsel and Corporate Secretary. Mr. Samuel will lead the Company's legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice. "We are pleased to welcome George to our leadership team and look forward to his contributions as we build Lineage into a leading cell therapy and cell transplant comp
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)
Craig Hallum initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00
Robert W. Baird initiated coverage of Lineage Cell Therapeutics with a rating of Outperform and set a new price target of $5.00
B. Riley Securities initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00